Literature DB >> 20410329

Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Daniel M Held1, Amy C Shurtleff, Scott Fields, Christopher Green, Julie Fong, Russell G A Jones, Dorothea Sesardic, Roland Buelow, Rae Lyn Burke.   

Abstract

New Zealand White (NZW) rabbits were immunized with several different nontoxic botulinum neurotoxin serotype B (BoNT/B) preparations in an effort to optimize the production of a rapid and highly potent, effective neutralizing antibody response. The immunogens included a recombinant heavy chain (rHc) protein produced in Escherichia coli, a commercially available formaldehyde-inactivated toxoid, and an alkylated toxoid produced by urea-iodoacetamide inactivation of the purified active toxin. All three immunogens elicited an antibody response to BoNT/B, detected by enzyme-linked immunosorbent assay (ELISA) and by toxin neutralization assay, by the use of two distinct mouse toxin challenge models. The induction period and the ultimate potency of the observed immune response varied for each immunogen, and the ELISA titer was not reliably predictive of the potency of toxin neutralization. The kinetics of the BoNT/B-specific binding immune response were nearly identical for the formaldehyde toxoid and alkylated toxoid immunogens, but immunization with the alkylated toxoid generated an approximately 10-fold higher neutralization potency that endured throughout the study, and after just 49 days, each milliliter of serum was capable of neutralizing 10(7) 50% lethal doses of the toxin. Overall, the immunization of rabbits with alkylated BoNT/B toxoid appears to have induced a neutralizing immune response more rapid and more potent than the responses generated by vaccination with formaldehyde toxoid or rHc preparations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410329      PMCID: PMC2884417          DOI: 10.1128/CVI.00493-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  33 in total

1.  Get effective polyclonal antisera in one month.

Authors:  Yuan Xin Hu; Ju Yuan Guo; Lu Shen; Yan Chen; Zu Chuan Zhang; Yong Lian Zhang
Journal:  Cell Res       Date:  2002-06       Impact factor: 25.617

2.  Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid.

Authors:  Yasushi Torii; Yoichi Tokumaru; Seijirou Kawaguchi; Nanae Izumi; Seika Maruyama; Masafumi Mukamoto; Shunji Kozaki; Motohide Takahashi
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

3.  Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain.

Authors:  Rakhi Agarwal; Subramaniam Eswaramoorthy; Desigan Kumaran; John J Dunn; Subramanyam Swaminathan
Journal:  Protein Expr Purif       Date:  2004-03       Impact factor: 1.650

4.  Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.

Authors:  Yu Zhou; Bal Ram Singh
Journal:  Protein Expr Purif       Date:  2004-03       Impact factor: 1.650

Review 5.  Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.

Authors:  Kathryn Turton; John A Chaddock; K Ravi Acharya
Journal:  Trends Biochem Sci       Date:  2002-11       Impact factor: 13.807

Review 6.  Bacterial toxins: a table of lethal amounts.

Authors:  D M Gill
Journal:  Microbiol Rev       Date:  1982-03

7.  Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active.

Authors:  S A Ahmed; L A Smith
Journal:  J Protein Chem       Date:  2000-08

8.  Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice.

Authors:  L A Woodward; H Arimitsu; R Hirst; K Oguma
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

9.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

Review 10.  Production of pharmaceutical proteins by transgenic animals.

Authors:  Louis-Marie Houdebine
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2008-02-19       Impact factor: 2.268

View more
  3 in total

1.  DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E.

Authors:  Aurore Burgain; Alice Rochard; Capucine Trollet; Christelle Mazuet; Michel R Popoff; Virginie Escriou; Daniel Scherman; Pascal Bigey
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

2.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

3.  New equine antitoxins to botulinum neurotoxins serotypes A and B.

Authors:  D Li; P Mattoo; J E Keller
Journal:  Biologicals       Date:  2012-05-05       Impact factor: 1.856

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.